Chardan Capital Markets analyst Gbola Amusa upgraded Audentes Therapeutics (NASDAQ: BOLD) from Neutral to Buy with a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Upgrades Upgrades